Marshall Wace LLP Sells 253,095 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Marshall Wace LLP reduced its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 20.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 982,048 shares of the company’s stock after selling 253,095 shares during the quarter. Marshall Wace LLP’s holdings in Cellebrite DI were worth $11,735,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of CLBT. Parallel Advisors LLC lifted its stake in shares of Cellebrite DI by 75.0% during the 4th quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock valued at $30,000 after buying an additional 1,500 shares in the last quarter. Quarry LP bought a new position in shares of Cellebrite DI in the fourth quarter worth about $36,000. Public Employees Retirement Association of Colorado purchased a new stake in shares of Cellebrite DI during the second quarter worth about $71,000. nVerses Capital LLC bought a new stake in Cellebrite DI during the 2nd quarter valued at approximately $103,000. Finally, TD Asset Management Inc purchased a new position in Cellebrite DI in the 2nd quarter worth approximately $121,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Trading Down 2.1 %

Shares of NASDAQ CLBT opened at $16.85 on Friday. Cellebrite DI Ltd. has a 12-month low of $6.36 and a 12-month high of $17.82. The firm’s 50-day moving average price is $15.61 and its 200-day moving average price is $12.85. The stock has a market capitalization of $3.47 billion, a price-to-earnings ratio of -29.05, a P/E/G ratio of 2.32 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Thursday, August 15th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.02. The business had revenue of $95.70 million for the quarter, compared to the consensus estimate of $91.94 million. Cellebrite DI had a positive return on equity of 5,902.06% and a negative net margin of 28.51%. The company’s quarterly revenue was up 24.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.05 earnings per share. On average, equities analysts predict that Cellebrite DI Ltd. will post 0.31 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Needham & Company LLC increased their price objective on shares of Cellebrite DI from $14.00 to $17.00 and gave the company a “buy” rating in a report on Friday, August 16th. Bank of America raised their target price on shares of Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $14.00 to $15.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. TD Cowen raised their price objective on Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Finally, Lake Street Capital lifted their target price on Cellebrite DI from $13.50 to $17.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI has a consensus rating of “Buy” and an average target price of $18.57.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.